CMND logo

Clearmind Medicine Inc.

CMND
Healthcare|Biotechnology|CA
$5.58
-0.27 (-4.55%)
DCF Value
$8.03
Tangible Book / Share
$65.03
Cash / Share
$80.54
Financing Filings (last 12 months)
9
Shelf registrations / offering prospectuses — latest Apr 30, 2026 (F-3). Possible dilution.

Upcoming Data Readouts (1)

Dec 2026
Est. completion
P1P2Alcohol Use Disorder
A First in Human Study of CMND-100 in Healthy and Alcohol Use Disorder (AUD) Subjects
NCT05913752n=84

Recent Press Releases

Clearmind Successfully Completes Patient Recruitment for the First Alcohol Use Disorder Cohort of its CMND-100 Phase I/IIa Clinical Trial
Oct 27, 2026 · GlobeNewsWire
Clearmind: Charging Robotics Launches Next-Generation Automated EV-Charging Technology for Robotaxis and Autonomous Fleets
Oct 12, 2026 · Globe News Wire
Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder
Oct 8, 2026 · GlobeNewsWire
Clearmind Advances Dialogue with U.S. Federal Government on Psychedelic Therapies, Submitting Recommendations to FDA
Oct 7, 2026 · GlobeNewsWire
Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations
Sep 23, 2026 · GlobeNewsWire
Clearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C.
Sep 17, 2026 · GlobeNewsWire
Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial
Sep 11, 2026 · GlobeNewsWire
Clearmind Medicine Receives Yale IRB Approval, Enabling Patient Recruitment for Parts B and C of CMND-100 Phase I/II Trial, Following Positive Safety Results
Sep 8, 2026 · GlobeNewsWire
Clearmind Medicine Signs Definitive Agreement to Acquire 51% Stake in Wireless Charging Company for Automated Parking and Robotaxis
Sep 4, 2026 · GlobeNewsWire
Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled
Sep 1, 2026 · GlobeNewsWire

SEC Filings (183)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Oct 27, 2026SC 13GPassive 5%+ stakeDocumentIndex
Oct 27, 20266-KForeign issuer reportDocumentIndex
Oct 16, 20266-KForeign issuer reportDocumentIndex
Oct 13, 20266-KForeign issuer reportDocumentIndex
Oct 8, 20266-KForeign issuer reportDocumentIndex
Oct 7, 20266-KForeign issuer reportDocumentIndex
Sep 30, 20266-KForeign issuer reportDocumentIndex
Sep 23, 20266-KForeign issuer reportDocumentIndex
Sep 17, 20266-KForeign issuer reportDocumentIndex
Sep 14, 20266-KForeign issuer reportDocumentIndex
Sep 10, 20266-KForeign issuer reportDocumentIndex
Sep 8, 20266-KForeign issuer reportDocumentIndex
Sep 4, 20266-KForeign issuer reportDocumentIndex
Sep 2, 20266-KForeign issuer reportDocumentIndex
Sep 1, 20266-KForeign issuer reportDocumentIndex
Aug 24, 20266-KForeign issuer reportDocumentIndex
Aug 12, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 11, 20266-KForeign issuer reportDocumentIndex
Aug 6, 20266-KForeign issuer reportDocumentIndex
Aug 3, 20266-KForeign issuer reportDocumentIndex
Jul 30, 20266-KForeign issuer reportDocumentIndex
Jul 20, 20266-KForeign issuer reportDocumentIndex
Jul 17, 20266-KForeign issuer reportDocumentIndex
Jul 16, 20266-KForeign issuer reportDocumentIndex
Jul 13, 20266-KForeign issuer reportDocumentIndex
Jul 10, 20266-KForeign issuer reportDocumentIndex
Jul 7, 20266-KForeign issuer reportDocumentIndex
Jun 29, 20266-KForeign issuer reportDocumentIndex
Jun 22, 20266-KForeign issuer reportDocumentIndex
Jun 18, 2026EFFECTDocumentIndex
Jun 18, 20266-KForeign issuer reportDocumentIndex
Jun 16, 20266-KForeign issuer reportDocumentIndex
Jun 15, 2026POS AMDocumentIndex
Jun 15, 20266-KForeign issuer reportDocumentIndex
Jun 12, 20266-KForeign issuer reportDocumentIndex
Jun 1, 20266-KForeign issuer reportDocumentIndex
May 29, 20266-KForeign issuer reportDocumentIndex
May 26, 20266-KForeign issuer reportDocumentIndex
May 19, 20266-KForeign issuer reportDocumentIndex
May 19, 20266-KForeign issuer reportDocumentIndex